Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESG401
- Development stage
- Phase 3
- Lead developer
- Shanghai Escugen Biotechnology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ESG401 is an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody targeting trophoblast cell-surface antigen 2 (TROP2), conjugated to the topoisomerase I inhibitor SN-38 via a proprietary stable-cleavable linker with a drug-to-antibody ratio (DAR) of 8. It is designed for the treatment of locally advanced or metastatic solid tumors, with particular focus on breast cancer subtypes such as triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer. ESG401 has demonstrated promising antitumor activity and a favorable safety profile in heavily pretreated patients, including those with brain metastases. The most common adverse events are hematologic toxicities such as neutropenia and leukopenia, along with fatigue, nausea, and vomiting[1][2][5][7].
- Other names
- cilamtib
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on ESG401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESG401.